Pherin Pharmaceuticals Inc. - Company Profile

BioCentury | Jan 1, 2007

Clinical News

PH80: Phase II data

...significantly higher for the PH80 group vs. placebo patients during the month following treatment (p<0.01). Pherin Pharmaceuticals Inc....

BioCentury | Jul 16, 2001

Company News

DoubleTwist deal

...Laboratories Fournier; M.D. Anderson Cancer Center; the National Cancer Institute; N.V. Organon; Oxagen Ltd. ; Pherin Pharmaceuticals Inc....

BioCentury | Feb 5, 2001

Clinical News

Vomeropherin: Began Phase I testing

Pherin Pharmaceuticals Inc., Mountain View, Calif. Product: Vomeropherin Business: Neurological Therapeutic category: Neurotransmission Target: Chemoreceptors on the vomeronasal organ Description: Chemoreceptor stimulator that modulates the hypothalamus Indication: Treat female anxiety disorders End point: Safety Status:...

BioCentury | Sep 11, 2000

Company News

Pherin, Taisho deal

...pay Pherin license and milestone fees for vomeropherin compounds. Pherin also is eligible for royalties. Pherin Pharmaceuticals Inc....

BioCentury | Nov 22, 1999

Company News

Pherin scientific advisory board update

Pherin Pharmaceuticals Inc. , Menlo Park, Calif. Business: Neurological Appointed: George Rosenkranz, formerly president and CEO of Syntex Corp.; Elias Corey, professor of chemistry at Harvard University WIR Staff...

BioCentury | Jul 12, 1999

Company News

Pherin, Janssen Pharmaceutica N.V. deal

...agreement, Johnson & Johnson Development Corp. purchased $1.5 million worth of Pherin convertible preferred stock. Pherin Pharmaceuticals Inc....

BioCentury | Oct 19, 1998

Clinical News

PH80 nasally administered vomeropherin compound: Phase I

Pherin Pharmaceuticals Inc. , Menlo Park, Calif. Product: PH80 nasally administered vomeropherin compound Indication: Treat premenstrual syndrome (PMS) Status: Pherin and partner N.V. Organon will begin on Nov. 1 Phase I single and multiple dose escalation...

BioCentury | Jul 28, 1997

Company News